2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 234

The Power Doppler Modalities Of 5 Ultrasound Machines Perform Very Differently, Ascertained By a Microvessel Flow Phantom
Abstract Number: 1601

The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus
Abstract Number: 2065

The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Abstract Number: 2052

The Prevalence and Pattern Of Self Reported Joint Symptoms In Cystic Fibrosis
Abstract Number: 1478

The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry
Abstract Number: 841

The Prevalence Of Fibromyalgia In The General Population – a Comparison Of The ACR 1990, 2010 and Modified 2010 Classification Criteria
Abstract Number: 2468

The Prevalence Of Sjogren’s Syndrome In Patients With Ankylosing Spondylitis
Abstract Number: 2593

The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Abstract Number: 1953

The Progression of Cartilage Damage in Rheumatoid Arthritis: A Three Year Prospective 3T- Magnetic Resonance Imaging Study Examining Predictive Factors
Abstract Number: 2021

The Proportion Of IgG4-Related Aortitis In Patients Diagnosed As Chronic Inflammation Of Aorta In Pathology
Abstract Number: 264

The Proportion Of Knee Osteoarthritis Patients In Southern Sweden That Seek Medical Car
Abstract Number: 1231

The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study
Abstract Number: 1780

The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Abstract Number: 1432

The Rate Of Serious Infections Remains Stable In Patients With Multiple Retreatments In Real life : Data From The “Auto Immunity and Rituximab” (AIR) Registry
Abstract Number: 1163

The Receptor For Advanced Glycation End Products (RAGE) As a Modulator Of Inflammatory Responses and Its Contribution To Gender-Specific Effects During Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].